Real-world effectiveness and tolerability of erenumab: A retrospective cohort study

作者：S.N. Kanaan, Gabrielle Hettie, Elizabeth Loder, Rebecca C. Burch · 发表于：Cephalalgia · 年份：2020 · DOI：10.1177/0333102420946725 · 被引用次数：94 · 研究领域：Migraine and Headache Studies、Pregnancy and Medication Impact、Pharmacovigilance and Adverse Drug Reactions

BACKGROUND: We aimed to systematically assess the effectiveness and tolerability of erenumab in a clinical setting, specifically a tertiary headache center. METHODS: This was a retrospective cohort study at the John Graham Headache Center of Brigham and Women's Hospital. All patients who received erenumab from a headache specialist at the Center from 17 May 2018 to 31 January 2019 were included. Patients were contacted and underwent a structured clinical interview including information about erenumab use, perceived benefit, adverse events (AEs), and a global assessment of benefit versus drawbacks. Chart review was performed for patients who could not be contacted. RESULTS: Four hundred and forty-four patients were initially identified and 418 were eligible. Two hundred and ninety-five participants completed the structured clinical interview portion of the study (response rate 70.6%). Seventy-four patient charts were additionally reviewed. Two hundred and forty-one participants had used erenumab. One hundred and sixty nine (70%) of participants experienced at least one adverse event, with constipation (43%), injection site reaction (24%), fatigue (15%), worsening headache (12%), and dizziness (11%) the five most commonly reported AEs. One hundred and sixty-eight participants (69.7%) felt that the benefits of erenumab outweighed any drawbacks. One hundred and fifty-one participants (62.7%) planned to continue using erenumab. Cost of treatment was cited by 12% of participants as...